Healthed provides pro-bono support for important research in general practice.
In 2018 the program changed from a 4-valent to 9-valent HPV vaccine and a 3-dose to 2-dose standard schedule. We assessed stakeholder perspectives on factors influencing program outcomes and impact as part of a comprehensive program evaluation. In late 2019 and early 2020, we conducted 26 interviews with 42 key stakeholder participants and received 1513 survey responses from stakeholders including general practice staff and school-based nurse immunisers. Findings included that the 2-dose schedule is better accepted by schools and students and has reduced program cost and resource requirements.
However, course completion rates have not increased as much as anticipated due to the 6-12 month dosing interval and reduced opportunities for school-based catch-up vaccination. Major reported barriers to increased vaccine coverage were absenteeism and consent form return. Vaccine hesitancy is not currently a major issue but remains a potential threat to the program. While Australia’s HPV vaccination program is perceived as highly successful, measures to further enhance the program’s impact and mitigate potential threats are important.
Swift C, Dey A, Rashid H, Clark K, Manocha R, Brotherton J, Beard F.
Vaccines (Basel). 2022 Nov 21;10(11):1976. doi: 10.3390/vaccines10111976.
PMID: 36423072 Free PMC article.
Based on this educational activity, complete these learning modules to gain additional CPD.
Listen to expert interviews.
Click to open in a new tab
PodcastsBrowse the latest articles from Healthed.
Once you confirm you’ve read this article you can complete a Patient Case Review to earn 0.5 hours CPD in the Reviewing Performance (RP) category.
Select ‘Confirm & learn‘ when you have read this article in its entirety and you will be taken to begin your Patient Case Review.
Menopause and MHT
Multiple sclerosis vs antibody disease
Using SGLT2 to reduce cardiovascular death in T2D
Peripheral arterial disease
